Welcome to BrainStorm Cell Therapeutics
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in Proceeds
Warrant Holders Exercising at a Premium; to Receive New Warrants
Hackensack, NJ & Petach Tikvah, Israel – January 8, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants issued in the June 13, 2014 private placement. These holders have agreed to exercise their warrants in full (for a total of approximately 2.5 million shares of common stock) at an exercise price of $5.22 per share, a 4% premium to the closing price of $5.03, which will generate gross cash proceeds of approximately $13 million. For each warrant exercised, BrainStorm agreed to issue 1.5 new warrants to the holders to purchase unregistered shares of common stock at an exercise price of $6.50. BrainStorm will file a registration statement covering the resale of the additional shares of common stock underlying the newly issued warrants. Read More...
Click here for our Company Presentation at the Stem Cell on the Mesa meeting in San Diego, October 2013.
Click here for a summary of the data presented at the American Academy of Neurology meeting, March 2013.